Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study

被引:84
|
作者
Shin, Ju-Young [1 ,2 ,3 ,4 ]
Roughead, Elizabeth E. [5 ]
Park, Byung-Joo [6 ]
Pratt, Nicole L. [5 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Res Inst, Ctr Clin Epidemiol, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada
[3] McGill Univ, Dept Biostat, Montreal, PQ, Canada
[4] McGill Univ, Dept Occupat Hlth, Montreal, PQ, Canada
[5] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
[6] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea
来源
BMJ-BRITISH MEDICAL JOURNAL | 2016年 / 353卷
基金
澳大利亚国家健康与医学研究理事会;
关键词
NERVOUS-SYSTEM STIMULANTS; AMBULATORY BLOOD-PRESSURE; RISK; EVENTS; ADOLESCENTS; MEDICATIONS; DESIGNS; DRUGS; DEATH;
D O I
10.1136/bmj.i2550
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. DESIGN Self controlled case series analysis. SETTING Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. PARTICIPANTS 1224 patients aged <= 17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate. MAIN OUTCOME MEASURES A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50). Incidence rate ratios were calculated with conditional Poisson regression and adjusted for time varying comorbidity and comedication. RESULTS Increased risk of arrhythmia was observed in all exposed time periods-that is, periods of treatment with methylphenidate-(incidence rate ratio 1.61, 95% confidence interval 1.48 to 1.74), and the risk was highest in the children who had congenital heart disease. No significant risk of myocardial infarction was observed for all exposed time periods (1.33, 0.90 to 1.98), though risk was higher in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. CONCLUSION The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly in children with mild ADHD.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] The Effects of Methylphenidate on Ventricular Repolarization Parameters in Children with Attention-Deficit Hyperactivity Disorder
    Tanir, Yasar
    Erbay, Muhammed Furkan
    Ozkan, Selcuk
    Ozdemir, Rahmi
    Orengul, Abdurrahman Cahid
    ALPHA PSYCHIATRY, 2023, 24 (05):
  • [12] Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: population-based cohort study
    Chen, Vincent Chin-Hung
    Chan, Hsiang-Lin
    Wu, Shu-, I
    Lu, Mong-Liang
    Dewey, Michael E.
    Stewart, Robert
    Lee, Charles Tzu-Chi
    BRITISH JOURNAL OF PSYCHIATRY, 2022, 220 (02) : 64 - 72
  • [13] Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder: An Update
    Awudu, Gariba A. H.
    Besag, Frank M. C.
    DRUG SAFETY, 2014, 37 (09) : 661 - 676
  • [14] Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design
    Raman, Sudha R.
    Marshall, Stephen W.
    Haynes, Kevin
    Gaynes, Bradley N.
    Naftel, Albert Jackson
    Stuermer, Til
    INJURY PREVENTION, 2013, 19 (03) : 164 - 170
  • [15] Assessment of cardiovascular functions in children with attention-deficit/hyperactivity disorder who are new users of methylphenidate
    Sargin, Fatma
    Oflaz, Mehmet Burhan
    Yar, Ahmet
    Baysal, Tamer
    KUWAIT MEDICAL JOURNAL, 2020, 52 (03): : 250 - 255
  • [16] Differential Effects of Predictors on Methylphenidate Initiation and Discontinuation Among Young People with Newly Diagnosed Attention-Deficit/Hyperactivity Disorder
    Chen, Chuan-Yu
    Yeh, Hsueh-Han
    Chen, Kuang-Hung
    Chang, I-Shou
    Wu, Erin Chia-Hsuan
    Lin, Keh-Ming
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (03) : 265 - 273
  • [17] Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder
    Lamberti, Marco
    Italiano, Domenico
    Guerriero, Laura
    D'Amico, Gessica
    Siracusano, Rosamaria
    Ingrassia, Massimo
    Germano, Eva
    Calabro, Maria Pia
    Spina, Edoardo
    Gagliano, Antonella
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1169 - 1174
  • [18] Using the Test of Variables of Attention to Determine the Effectiveness of Modafinil in Children With Attention-Deficit Hyperactivity Disorder (ADHD): A Prospective Methylphenidate-Controlled Trial
    Goez, Helly R.
    Scott, Ori
    Nevo, Neta
    Bennett-Back, Odeya
    Zelnik, Nathanel
    JOURNAL OF CHILD NEUROLOGY, 2012, 27 (12) : 1547 - 1552
  • [19] Safety of Attention-Deficit/Hyperactivity Disorder Medications in Children: An Intensive Pharmacosurveillance Monitoring Study
    Ruggiero, Simona
    Rafaniello, Concetta
    Bravaccio, Carmela
    Grimaldi, Giampina
    Granato, Rosario
    Pascotto, Antonio
    Sportiello, Liberata
    Parretta, Elisabetta
    Rinaldi, Barbara
    Panei, Pietro
    Rossi, Francesco
    Capuano, Annalisa
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2012, 22 (06) : 415 - 422
  • [20] Sleep and daytime sleepiness in methylphenidate medicated and un-medicated children with attention-deficit/hyperactivity disorder (ADHD)
    Cockcroft, K.
    Ashwal, J.
    Bentley, A.
    AFRICAN JOURNAL OF PSYCHIATRY, 2009, 12 (04) : 275 - 279